FOSAMAX
Total Payments
$245,570
Transactions
7
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $23,903 | 2 | 0 |
| 2018 | $122,434 | 3 | 0 |
| 2017 | $99,234 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $245,570 | 7 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Validation of in vivo cortical bone microarchitecture and strength measurements and their relation with fracture. | Merck Sharp & Dohme Corporation | $122,434 | 0 |
| Lower limb geometry in individuals with atypical femoral fractures | Merck Sharp & Dohme Corporation | $63,379 | 0 |
| An observational case-control study to validate the association between RBMS3 and risk of osteonecrosis of the jaw in subjects receiving anti-resorptive agents | Merck Sharp & Dohme Corporation | $59,758 | 0 |
Top Doctors Receiving Payments for FOSAMAX
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New York, NY | $245,570 | 7 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $245,570
Product Information
- Type Drug
- Total Payments $245,570
- Total Doctors 0
- Transactions 7
About FOSAMAX
FOSAMAX is a drug associated with $245,570 in payments to 0 healthcare providers, recorded across 7 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2019. In 2019, $23,903 was paid across 2 transactions to 0 doctors.
The most common payment nature for FOSAMAX is "Unspecified" ($245,570, 100.0% of total).
FOSAMAX is associated with 3 research studies, including "Validation of in vivo cortical bone microarchitecture and strength measurements and their relation with fracture." ($122,434).